Windlas Biotech
Close ·
- P/E
- 27.57
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures at the close · EPS basis: Standalone · TTM
- ROCE
- 15.90%
- Debt to Equity
- 0.06
- EPS (TTM)
- ₹31.68
- Book Value
- ₹281.35
- Market Cap
- —
- P/E (TTM)
- 27.57
- P/B
- 3.10
- ROE
- 12.20%
- Dividend Yield
- 0.72%
- EBITDA
- ₹123 Cr
- 52W High
- ₹1,181.90
- 52W Low
- ₹697.40
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 50
- Average
- Returns, margins, earnings quality 22% weight
- Valuation
- 66
- Strong
- Cheap vs sector & own history 24% weight
- Growth
- 67
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 66
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 38
- Weak
- Trend strength, vol-adjusted 12% weight
- Ownership
- 35
- Poor
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
4- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 19.8%
- Promoter holding has increased by 1.41% over last quarter.
- Company's working capital requirements have reduced from 21.4 days to 14.4 days
Weaknesses
1- Company has a low return on equity of 12.8% over last 3 years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 10 | 5 | 4 |
| Oscillators | Bullish | 1 | 5 | 3 |
| Moving Averages | Strong Bearish | 9 | 0 | 1 |
Oscillators
Bullish
Overall
Strong Bearish
Moving Averages
Strong Bearish
Key readings
- RSI (14)
- 37.63
- Neutral
- MACD (12,26,9)
- −37.29
- Bullish
- SMA (50)
- 1,012.21
- Bearish
- SMA (200)
- 870.46
- Bullish
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | +12.68% |
|---|---|
| 5Y | +16.13% |
| 3Y | +20.79% |
| 1Y | +18.95% |
| TTM | +18.36% |
Net profit
| 10Y | +29.44% |
|---|---|
| 5Y | +67.54% |
| 3Y | +15.35% |
| 1Y | +8.20% |
| TTM | +3.08% |
Operating cash flow
| 10Y | +8.37% |
|---|---|
| 5Y | +57.02% |
| 3Y | +19.84% |
| 1Y | +54.41% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +4.32 pp |
|---|---|
| 5Y | −1.23 pp |
| 3Y | −0.08 pp |
| 1Y | −0.75 pp |
| TTM | −1.54 pp |
Revenue by year
| Mar 2017 | ₹315 Cr |
|---|---|
| Mar 2018 | ₹320 Cr |
| Mar 2019 | ₹288 Cr |
| Mar 2020 | ₹329 Cr |
| Mar 2021 | ₹428 Cr |
| Mar 2022 | ₹466 Cr |
| Mar 2023 | ₹513 Cr |
| Mar 2024 | ₹631 Cr |
| Mar 2025 | ₹760 Cr |
| Mar 2026 | ₹904 Cr |
Net profit by year
| Mar 2017 | ₹9.00 Cr |
|---|---|
| Mar 2018 | ₹17.00 Cr |
| Mar 2019 | ₹22.00 Cr |
| Mar 2020 | ₹22.00 Cr |
| Mar 2021 | ₹5.00 Cr |
| Mar 2022 | ₹39.00 Cr |
| Mar 2023 | ₹43.00 Cr |
| Mar 2024 | ₹58.00 Cr |
| Mar 2025 | ₹61.00 Cr |
| Mar 2026 | ₹66.00 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 145 | 153 | 162 | 171 | 175 | 187 | 195 | 203 | 210 | 222 | 233 | 238 | 248 |
| Expenses | 128 | 134 | 142 | 149 | 154 | 164 | 170 | 177 | 184 | 194 | 209 | 213 | 221 |
| Operating Profit | 17 | 19 | 20 | 22 | 21 | 23 | 25 | 26 | 27 | 29 | 24 | 25 | 27 |
| OPM % | 12% | 12% | 13% | 13% | 12% | 12% | 13% | 13% | 13% | 13% | 10% | 11% | 11% |
| Other Income | 3 | 3 | 3 | 4 | 4 | 5 | 4 | 5 | 5 | 4 | 5 | 4 | 5 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| Depreciation | 3 | 3 | 3 | 4 | 6 | 6 | 7 | 8 | 7 | 8 | 8 | 8 | 7 |
| PBT | 16 | 18 | 20 | 23 | 18 | 20 | 20 | 21 | 23 | 24 | 20 | 20 | 23 |
| Tax % | 26% | 23% | 24% | 25% | 26% | 23% | 24% | 22% | 24% | 25% | 25% | 21% | 23% |
| Net Profit | 12 | 14 | 15 | 17 | 13 | 16 | 15 | 16 | 18 | 18 | 15 | 16 | 18 |
| EPS (₹) | 5.8 | 6.75 | 7.26 | 8.15 | 6.45 | 7.49 | 7.29 | 7.77 | 8.43 | 8.45 | 7.09 | 7.59 | 8.55 |
Profit & Loss
₹ Cr| Particulars | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 274 | 315 | 320 | 288 | 329 | 428 | 466 | 513 | 631 | 760 | 904 | 942 |
| Expenses | 253 | 290 | 284 | 244 | 288 | 373 | 413 | 453 | 553 | 666 | 799 | 837 |
| Operating Profit | 20 | 25 | 36 | 44 | 41 | 55 | 53 | 60 | 78 | 94 | 105 | 105 |
| OPM % | 7% | 8% | 11% | 15% | 12% | 13% | 11% | 12% | 12% | 12% | 12% | 11% |
| Other Income | 1 | 4 | 5 | 2 | 1 | −29 | 7 | 10 | 13 | 18 | 18 | 18 |
| Interest | 7 | 5 | 5 | 4 | 2 | 1 | 1 | 1 | 1 | 4 | 5 | 5 |
| Depreciation | 9 | 9 | 11 | 8 | 9 | 13 | 12 | 12 | 13 | 28 | 31 | 31 |
| PBT | 6 | 14 | 25 | 35 | 31 | 11 | 46 | 57 | 77 | 79 | 87 | 87 |
| Tax % | 20% | 35% | 33% | 36% | 27% | 55% | 16% | 25% | 25% | 24% | 24% | — |
| Net Profit | 5 | 9 | 17 | 22 | 22 | 5 | 39 | 43 | 58 | 61 | 66 | 66 |
| EPS (₹) | 8.14 | 16.41 | 30.24 | 35.05 | 35.03 | 7.81 | 17.69 | 20.05 | 27.95 | 28.94 | 31.48 | 31.68 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 20% | 20% | 20% | 20% | 20% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 11 | 10 | 10 | 10 | 11 |
| Reserves | 132 | 141 | 158 | 188 | 210 | 193 | 384 | 392 | 440 | 495 | 570 |
| Borrowings | 53 | 62 | 43 | 30 | 27 | 32 | 7 | 5 | 4 | 33 | 35 |
| Other Liabilities | 90 | 94 | 93 | 73 | 100 | 65 | 89 | 121 | 172 | 222 | 291 |
| Total Liabilities | 281 | 304 | 299 | 297 | 344 | 296 | 491 | 529 | 626 | 760 | 907 |
| Fixed Assets | 56 | 56 | 58 | 62 | 68 | 96 | 91 | 109 | 179 | 223 | 213 |
| CWIP | 9 | 15 | 11 | 5 | 0 | 0 | 8 | 15 | 6 | 5 | 60 |
| Investments | 95 | 121 | 123 | 121 | 121 | 23 | 65 | 107 | 173 | 223 | 268 |
| Other Assets | 121 | 111 | 107 | 110 | 154 | 177 | 327 | 298 | 268 | 308 | 366 |
| Total Assets | 281 | 304 | 299 | 297 | 344 | 296 | 491 | 529 | 626 | 760 | 907 |
Cash Flow
₹ Cr| Particulars | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 47 | 7 | 39 | 22 | 21 | 11 | 9 | 61 | 109 | 68 | 105 |
| Investing | −62 | −39 | −11 | −7 | −9 | −20 | −154 | −14 | −92 | −74 | −92 |
| Financing | 38 | 5 | −25 | −8 | −6 | 1 | 130 | −44 | −15 | 1 | −13 |
| Net Cash Flow | 24 | −27 | 4 | 7 | 5 | −8 | −15 | 3 | 2 | −5 | 0 |
| Free Cash Flow | 35 | −8 | 28 | 12 | 11 | 6 | −6 | −9 | 71 | 16 | 37 |
| CFO/OP | 249 | 34 | 122 | 80 | 84 | 33 | 34 | 117 | 163 | 95 | 115 |
Ratios
| Particulars | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 74 | 70 | 68 | 79 | 72 | 68 | 87 | 83 | 79 | 80 | 92 |
| Inventory Days | 49 | 62 | 44 | 38 | 85 | 55 | 71 | 84 | 57 | 63 | 40 |
| Days Payable | 137 | 120 | 124 | 117 | 143 | 53 | 76 | 98 | 121 | 138 | 156 |
| Cash Conversion Cycle | −14 | 13 | −12 | 0 | 13 | 70 | 82 | 69 | 15 | 6 | −24 |
| Working Capital Days | −46 | −37 | 2 | −12 | 3 | 40 | 86 | 72 | 32 | 18 | 14 |
| ROCE % | — | 10% | 13% | 18% | 14% | 19% | 15% | 14% | 18% | 17% | 16% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Windlas Biotech insights
66 extracted metrics across FY16–FY27.
Documents
- Q1 FY27 concall · Aug 2026Transcript PPT Recording
- Concall · May 2026Transcript PPT Recording
- Q3 FY26 concall · Feb 2026Transcript PPT
- Q2 FY26 concall · Nov 2025Transcript PPT Recording
- Q1 FY26 concall · Aug 2025Transcript PPT
- 7 Apr 2025
- 5 Feb 2024
- 24 Sep 2021
- 15 Dec 2016
- 2 Mar 2016
- General announcements 30 Oct 2026
- General announcements 30 Oct 2026
Frequently Asked Questions about Windlas Biotech
What does Windlas Biotech Ltd do?
Where is Windlas Biotech Ltd (WINDLAS) listed?
Which sector does Windlas Biotech Ltd belong to?
What is the PE ratio of Windlas Biotech Ltd?
What is the 52-week high and low of Windlas Biotech Ltd?
Does Windlas Biotech Ltd pay dividends?
What is the Return on Equity (ROE) of Windlas Biotech Ltd?
Company Information
Windlas Biotech Ltd is a leading domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). The company manufactures both solid and liquid pharmaceutical dosage forms and provides a comprehensive range of CDMO services ranging from product discovery, product development, and commercial manufacturing of generic products, including complex generics.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/WINDLAS.md for Windlas Biotech Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.